Granted Patent
B2
US 12,235,270 · App. 17/395,103 · Granted Feb 25, 2025
Depleting tumor-specific tregs
Assignee:
MEMORIAL SLOAN KETTERING CANCER CENTER
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides, among other things, methods and compositions for diagnosing and/or treating cancer by targeting CCR8. In particular, the present invention provides technologies for depleting Treg cells, and particularly tumor-infiltrating Treg cells.
Claims (15)
1. A method of detecting and/or characterizing binding between an anti-CCR8 antibody agent and CCR8, the method comprising steps of:
contacting the anti-CCR8 antibody agent with cells or tissue from a sample; and
detecting binding between the anti-CCR8 antibody agent with CCR8 in or on the cells or tissue;
wherein the contacting is performed in vitro;
wherein the sample is from a tumor in a human subject;
further comprising a step of determining that the detected binding is with CCR8 in or on tumor-infiltrating Treg cells; and
wherein the anti-CCR8 antibody agent comprises a detectable moiety that is a radioactive, fluorescent, chemiluminescent, or phosphorescent moiety.
2. The method of claim 1 , further comprising administering one or more immunomodulatory therapeutic modalities to the subject.
3. The method of claim 1 , wherein the step of detecting comprises detecting binding between the anti-CCR8 antibody agent with CCR8 in the sample, further comprising a step of administering anti-tumor therapy to the subject from whom the sample was obtained.
4. The method of claim 3 , wherein the anti-tumor therapy comprises an anti-CCR4 antibody agent.
5. The method of claim 4 , wherein the anti-CCR4 antibody agent comprises a bi-specific antibody agent targeting CCR4 and CCR8.
6. The method of claim 3 , wherein the anti-tumor therapy comprises a second anti-CCR8 antibody, or CCR8-binding portion thereof.
7. The method of claim 6 , wherein the second anti-CCR8 antibody, or binding portion thereof, is the same as the first anti-CCR8 antibody, or binding portion thereof.
8. The method of claim 1 , wherein the tumor is a solid tumor.
9. The method of claim 8 , wherein the solid tumor is a breast tumor.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 5, 2021
From: RUDENSKY, ALEXANDER; PLITAS, GEORGE
To: MEMORIAL SLOAN KETTERING CANCER CENTER
Reel/Frame 058026/0942 →
Continuity (4)
Division
14698600
· Apr 28, 2015
Provisional Application
61985329
· Apr 28, 2014
References Cited (131)
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5078998A
· Bevan et al.
· 1992
[cited by applicant]
US 5091513A
· Huston et al.
· 1992
[cited by applicant]
US 5225539A
· Winter
· 1993
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5693761A
· Queen et al.
· 1997
[cited by applicant]
US 5693762A
· Queen et al.
· 1997
[cited by applicant]
US 5869619A
· Studnicka
· 1999
[cited by applicant]
US 6180370B1
· Queen et al.
· 2001
[cited by applicant]
US 6548640B1
· Winter
· 2003
[cited by applicant]
US 6881557B2
· Foote
· 2005
[cited by applicant]
US 6982321B2
· Winter
· 2006
[cited by applicant]
US 7241444B2
· Goetsch et al.
· 2007
[cited by applicant]
US 20070009544A1
· Eisenberg et al.
· 2007
[cited by applicant]
US 20090214533A1
· Clynes
· 2009
[cited by applicant]
WO WO2013131010A2
· 2013
[cited by examiner]
Al-Shibli, K.I. et al., Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer, Clin. Cancer Res., 14(16):5220-5227 (2008).
[cited by applicant]
Amedei, A. et al., Novel immunotherapeutic strategies of gastric cancer treatment, J. Biomed. Biotechnol., 2011:437348 (2011).
[cited by applicant]
Author Not Known, MJ [G11] (ATCC@ CRL8294™), Product Sheet, American Type Culture Collection, 3 pages (2013).
[cited by applicant]
Balachandran, V.P., et al., Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido, Nat. Med., 17(9):1094-100 (2011).
[cited by applicant]
Barzaghi, F. et al., Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity, Front. Immunol., 3:211 (2012).
[cited by applicant]
Bates, G.J. et al., Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse, J. Clin. Oncol., 24(34):5373-80 (2006).
[cited by applicant]
Bindea, G. et al., Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer, Immunity, 39(4):782-95 (2013).
[cited by applicant]
Bohling, S.D. and Allison, K.H., Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target, Mod. Pathol., 21(12):1527-32 (2008).
[cited by applicant]
Bos, P.D. et al., Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy, J. Exp. Med., 210(11):2435-66 (2013).
[cited by applicant]
Brahmer, J.R. et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med., 366(26):2455-65 (2012).
[cited by applicant]
Buckner, J.H., Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases, Nat. Rev. Immunol., 10(12):849-59 (2010).
[cited by applicant]
Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours, Nature, 490(7418):61-70 (2012).
[cited by applicant]
Casares, N. et al., A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice, J. Immunol., 185(9):5150-9 (2010).
[cited by applicant]
Casset, F. et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design, Biochem. Biophys. Res. Commun., 307(1):198-205 (2003).
[cited by applicant]
Cetin, K. et al., Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program, Clin. Epidemiol., 3:139-48 (2011).
[cited by applicant]
Chaudhry, A. and Rudensky, A.Y., Control of inflammation by integration of environmental cues by regulatory T cells, J. Clin. Invest., 123(3):939-44 (2013).
[cited by applicant]
Chaudhry, A. et al., CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner, Science, 326(5955):986-91 (2009).
[cited by applicant]
Chen, C.A., et al., Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis, Mol. Ther., 18(6):1233-43 (2010).
[cited by applicant]
Chen, Y. et al., Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-Matured Fab in Complex with Antigen, J. Mol. Biol., 293(4):865-81 (1999).
[cited by applicant]
Chinen, T. and Rudensky, A.Y., The effects of commensal microbiota on immune cell subsets and inflammatory responses, Immunol. Rev., 245(1):45-55 (2012).
[cited by applicant]
Chinen, T. et al., A critical role for regulatory T cell-mediated control of inflammation in the absence of commensal microbiota, J. Exp. Med., 207(11):2323-30 (2010).
[cited by applicant]
Conforti, R. et al., Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands, Cancer Res., 70(2):490-500 (2010).
[cited by applicant]
Curiel, T.J. et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat. Med., 10(9):942-9 (2004).
[cited by applicant]
De Pascalis, R. et al., Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody…
[cited by applicant]
Deleeuw, R.J. et al., The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature, Clin. Cancer Res., 18(11):3022-9 (2012).
[cited by applicant]
Denardo, D.G. et al., CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages, Cancer Cell, 16(2):91-102 (2009).
[cited by applicant]
Deng, B. et al., Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGF-?1 in gastric cancer, PLoS One, 8(5):e63777 (2013).
[cited by applicant]
Dhamne, C. et al., Peripheral and thymic foxp3(+) regulatory T cells in search of origin, distinction, and function, Front. Immunol., 4:253 (2013).
[cited by applicant]
Drakes, M.L and Stiff, P.J., Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy, Immunotargets Ther., 3:151-165 (2014).
[cited by applicant]
Ducancel, F. and Muller, B.H., Molecular engineering of antibodies for therapeutic and diagnostic purposes, MAbs., 4(4):445-57 (2012).
[cited by applicant]
Dunn, G.P. et al., The immunobiology of cancer immunosurveillance and immunoediting, Immunity, 21(2):137-48 (2004).
[cited by applicant]
Ercolini, A.M. et al., Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response, J. Exp. Med., 201(10):1591-602 (2005).
[cited by applicant]
Fellmann, C. et al., An optimized microRNA backbone for effective single-copy RNAi, Cell Rep., 5(6):1704-13 (2013).
[cited by applicant]
Fontenot, J.D. et al., Foxp3 programs the development and function of CD4+CD25+ regulatory T cells, Nat. Immunol., 4(4):330-6 (2003).
[cited by applicant]
Formenti, S.C. and Demaria, S., Systemic effects of local radiotherapy, Lancet Oncol., 10(7):718-26 (2009).
[cited by applicant]
Galon, J. et al., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313(5795):1960-4 (2006).
[cited by applicant]
Gao, J. et al., Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal, Sci Signal., 6(269): p. 11, 34 pages (2014).
[cited by applicant]
Gerner, M.Y. et al., Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes, Immunity, 37(2):364-76 (2012).
[cited by applicant]
Gobert, M. et al., Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome, Cancer Res., 69(5):2000-9 (…
[cited by applicant]
Hiraoka, N. et al., Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions, Clin. Cancer Res., 12(18):5423-34 (2006).
[cited by applicant]
Hodi, F.S. et al., Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363(8):711-23 (2010).
[cited by applicant]
Hoelzinger, D. B. et al., Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses, J. Immunol., 184(12): 6833-42 (2010).
[cited by applicant]
Holm, P. et al., Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1, Mol. Immunol., 44(6):1075-1084 (2007).
[cited by applicant]
Hooper, L.V. et al., Interactions between the microbiota and the immune system, Science, 336(6086):1268-73 (2012).
[cited by applicant]
Hori, S. et al., Control of regulatory T cell development by the transcription factor Foxp3, Science, 299(5609):1057-61 (2003).
[cited by applicant]
Iellem, A. et al., Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors CCR4 and CCR8 by CD4+CD25+ Regulatory T Cells, J. Exp. Med., 194(6):847-853 (2001).
[cited by applicant]
Iida, S. et al., Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIlla, Clin. Cancer Res.…
[cited by applicant]
Islam, S.A. et al., Identification of human CCR8 as a CCL18 receptor, J. Exp. Med., 210(10):1889-98 (2013).
[cited by applicant]
Islam, S.A. et al., Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells, Nat. Immunol., 12(2):167-77 (2011).
[cited by applicant]
Josefowicz, S.Z. et al., Extrathymically generated regulatory T cells control mucosal TH2 inflammation, Nature, 482(7385):395-9 (2012).
[cited by applicant]
Josefowicz, S.Z. et al., Regulatory T cells: mechanisms of differentiation and function, Annu. Rev. Immunol., 30:531-64 (2012).
[cited by applicant]
Kantoff, P.W. et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N. Engl. J. Med., 363(5):411-22 (2010).
[cited by applicant]
Kim, J. et al., Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice, J. Immunol., 183(12):7631-4 (2009).
[cited by applicant]
Kim, J.M. et al., Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice, Nat. Immunol., 8(2):191-7 (2007).
[cited by applicant]
Klages, K. et al., Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma, Cancer Res., 70(20):7788-99 (2010).
[cited by applicant]
Ko, K. et al., Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells, J. Exp. Med., 202(7):885-91 (2005).
[cited by applicant]
Koch, M.A. et al., The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation, Nat. Immunol., 10(6):595-602 (2009).
[cited by applicant]
Komatsu, N. and Hori, S., Full restoration of peripheral Foxp3+ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras, Proc. Natl. Acad. Sci. U S A, 104(21):8959-64 (2007).
[cited by applicant]
Lal, G. et al., Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation, J. Immunol., 182(1):259-73 (2009).
[cited by applicant]
Lehtimäki, S. and Lahesmaa, R., Regulatory T Cells Control Immune Responses through Their Non-Redundant Tissue Specific Features, Front. Immunol., 4:294 (2013).
[cited by applicant]
Li, Y. and Xie, X., A mixture model for expression deconvolution from RNA-seq in heterogeneous tissues, BMC Bioinformatics, 14 Suppl 5:S11, 11 pages (2013).
[cited by applicant]
Littman, D.R. and Rudensky, A.Y., Th17 and regulatory T cells in mediating and restraining inflammation, Cell, 140(6):845-58 (2010).
[cited by applicant]
Loi, S. et al., Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin …
[cited by applicant]
MacCallum, R. et al., Antibody-antigen Interactions: Contact Analysis and Binding Site Topography, J. Mol. Biol., 262(5):732-745 (1996).
[cited by applicant]
Michaud, M. et al., Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice, Science, 334(6062):1573-7 (2011).
[cited by applicant]
Mizukami, Y. et al., Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer, Br. J. Cancer., 98(1):148-53 (2008).
[cited by applicant]
Mulligan, A.M. et al., Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry, Clin. Cancer Res., 19(2):336-46 (2013).
[cited by applicant]
Ott, P.A. et al., CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients, Clin. Cancer Res., 19(19):5300-9 (2013).
[cited by applicant]
Pagès, F. et al., Immune infiltration in human tumors: a prognostic factor that should not be ignored, Oncogene, 29(8):1093-102 (2010).
[cited by applicant]
Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer., 12(4):252-64 (2012).
[cited by applicant]
Peggs, K.S. et al., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies, J. Exp. Med., 206(8):1717-25 (2009).
[cited by applicant]
Peng, G. et al., Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function, Science, 309(5739):1380-4 (2005).
[cited by applicant]
Pere, H. et al., Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer, Oncoimmunology, 1(3):326-333 (2012).
[cited by applicant]
Perou, C.M., Molecular stratification of triple-negative breast cancers, Oncologist, 16 Suppl 1:61-70 (2011).
[cited by applicant]
Petersen, R.P. et al., Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients, Cancer, 107(12):2866-72 (2006).
[cited by applicant]
Piconese, S. et al., OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection, J. Exp. Med., 205(4):825-39 (2008).
[cited by applicant]
Prall, F. et al., Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability, Hum. Pathol., 35(7):808-16 (2004).
[cited by applicant]
Robert, C. et al., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N. Engl. J. Med., 364(26):2517-26 (2011).
[cited by applicant]
Rubtsov, Y.P. et al., Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces, Immunity, 28(4):546-58 (2008).
[cited by applicant]
Rudikoff, S. et al., Single amino acid substitution altering antigen-binding specificity, Proc. Natl. Acad. Sci. USA. 79(6):1979-1983 (1982).
[cited by applicant]
Samstein, R.M. et al., Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict, Cell, 150(1):29-38 (2012).
[cited by applicant]
Sato, E. et al., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer, Proc. Natl. Acad. Sci. U S A, 102(51):18538-43 (200…
[cited by applicant]
Savage, P.A. et al., Basic principles of tumor-associated regulatory T cell biology, Trends Immunol., 34(1):33-40 (2013).
[cited by applicant]
Scott, A.M. et al., Antibody therapy of cancer, Nat. Rev. Cancer, 12(4):278-87 (2012).
[cited by applicant]
Shalem, O. et al., Genome-scale CRISPR-Cas9 knockout screening in human cells, Science, 343(6166):84-7 (2014).
[cited by applicant]
Sharma, P. et al., Novel cancer immunotherapy agents with survival benefit: recent successes and next steps, Nat. Rev. Cancer, 11(11):805-12 (2011).
[cited by applicant]
Shi, L. et al., Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer, Cancer Immunol. Immunother., 61(12):2251-9 (2012).
[cited by applicant]
Shimizu, K. et al., Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer, J. Thorac. Oncol., 5(5):585-90 …
[cited by applicant]
Simpson, T.R. et al., Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma, J. Exp. Med., 210(9):1695-710 (2013).
[cited by applicant]
Stephens, G.L. et al., Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells, J. Immunol., 173(8):5008-20 (2004).
[cited by applicant]
Suzuki, K. et al., Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor ?2 (IL-12R?2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence, J. …
[cited by applicant]
Takahashi, R. et al., Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome, J. Immunol., 182(12):8071-9 (2009).
[cited by applicant]
Tan, M.C. et al., Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer, J. Immunol., 182(3):1746-55 (2009).
[cited by applicant]
Teng, M.W. et al., Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth, Cancer Res., 70(20):7800-9 (2010).
[cited by applicant]
Topalian, S. L. et al., Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, the New England Journal of Medicine, 366(26):2443-2454 (2012).
[cited by applicant]
Turk, M.J. et al., Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells, J. Exp. Med., 200(6):771-82 (2004).
[cited by applicant]
Vajdos, F. et al., Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis, J. Mol. Biol., 320(2):415-428 (2002).
[cited by applicant]
Valzasina, B, et al., Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR, Blood, 105(7):2845-51 (2005).
[cited by applicant]
Verbsky, J.W. and Chatila, T.A., Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases, Curr. Opin. Pediatr., 25(6):708-14 (2…
[cited by applicant]
Viguier, M. et al., Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells, J. Immunol., 173(2):1444-53 (2004).
[cited by applicant]
Wang, C. et al., Optimal Population of FoxP3+ T Cells in Tumors Requires an Antigen Priming-Dependent Trafficking Receptor Switch, PLoS ONE, 7(1): e30793 (2012).
[cited by applicant]
Wang, L. et al., Foxp3+ T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity, Blood, 121(18):3631-9 (2013).
[cited by applicant]
Wolf, D. et al., The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer, Clin. Cancer Res., 11(23):8326-31 (2005).
[cited by applicant]
Wu, H. et al., Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues, J. Mol. Biol., 294(1):151-162 (1999).
[cited by applicant]
Yagi, H. et al., Crucial role of FOXP3 in the development and function of human CD25+CD4+regulatory T cells, Int. Immunol., 16(11):1643-56 (2004).
[cited by applicant]
Yan, M. et al., Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers, Breast Cancer Res., 13(2):R47 (2011).
[cited by applicant]
Yang, H. et al., One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering, Cell, 154(6):1370-9 (2013).
[cited by applicant]
Zheng, Y. et al., Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses, Nature, 458(7236):351-6 (2009).
[cited by applicant]
Zhou, S. et al., CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer, PLoS One, 8(9):e74430 (2013).
[cited by applicant]
Cited By (1)